The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press10010.17650/1818-8338-2011-5-3-ORIGINAL INVESTIGATIONSОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕHELICOBACTER PYLORI-ASSOCIATED INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROMEHELICOBACTER PYLORI-АССОЦИИРОВАННОЕ ВОСПАЛЕНИЕ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМPavlovO. N.ПавловО. Н.
Russian Federation
o.n.pavlov@mail.ruRoad Clinical Hospital at the Yaroslavl station RZDНУЗ Дорожная клиническая больница на станции Ярославль ОАО РЖД150720115343481607201416072014Copyright ©; 2011, Pavlov O.N.Copyright ©; 2011, Павлов О.Н.2011Pavlov O.N.Павлов О.Н.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/100

The aim – assessment of the prevalence of seropositivity to Helicobacter pylori infection and laboratory comparative study of the peripheralblood in patients depending on the course of coronary heart disease (CHD).

Materials and methods. Observation of 100 patients with coronary artery disease and 40 control patients is presented. Investigation indicatorsof clinical blood tests, biochemical blood analysis and determination of immunoglobulin antibody titer against Helicobacter pylori.

Results. In patients with coronary artery disease signs of systemic inflammation associated with the development of acute coronary syndrome are marked with increased antibody titers to infection Helicobacter pylori.

Conclusion. A history of coronary artery disease in patients with Helicobacter pylori-associated gastroduodenal pathology should be considered as a factor that increases the likelihood of unstable coronary desease course. Detected in patients with coronary artery disease signs of systemic inflammation with an increase in titer of antibodies to Helicobacter pylori infection associated with development of acute coronary syndrome.

ischemic heart diseaseinflammationantibodiesHelicobacter pyloriишемическая болезнь сердцавоспалениеантителаHelicobacter pylori1. Wyrobiec G., Helewski K., Stepien M. Ischemic heart disease and chronic Helicobacter pylori nfection – present views (in Polish). Wiad Lek 2001;54(11–12):684–92.Wyrobiec G., Helewski K., Stepien M. Ischemic heart disease and chronic Helicobacter pylori nfection – present views (in Polish). Wiad Lek 2001;54(11–12):684–92.2. Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol 2003;29(4):351–9.Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol 2003;29(4):351–9.3. Strachan D.P. Non-gastrointestinal consequences of Helicobacter pylori infection. Br Med Bull 1998;54(1):87–93.Strachan D.P. Non-gastrointestinal consequences of Helicobacter pylori infection. Br Med Bull 1998;54(1):87–93.4. Schoecksnadel K., Frick B., Wirleitner C., et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5(1):107–18.Schoecksnadel K., Frick B., Wirleitner C., et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5(1):107–18.5. Strandberg T.E., Tilvis R.S., Vuoristo M., et al. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population. BMJ 1997;314(7090):1317–8.Strandberg T.E., Tilvis R.S., Vuoristo M., et al. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population. BMJ 1997;314(7090):1317–8.6. Patel P., Menall M.A., Carrington D., et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311(7007):711–4.Patel P., Menall M.A., Carrington D., et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311(7007):711–4.7. O’Donnell C.J., Levy D. Weighing the evidence for infection as a risk factor for coronary heart disease. Curr Cardiol Rep 2000;2(4):280–7.O’Donnell C.J., Levy D. Weighing the evidence for infection as a risk factor for coronary heart disease. Curr Cardiol Rep 2000;2(4):280–7.8. Pellicano R., Peyre S., Astegiano M., et al. Updated review (2006) on Helicobacter pylori as a potential target for the therapy of ischemic heart disease. Panminerva Med 2006;48(4):241–6.Pellicano R., Peyre S., Astegiano M., et al. Updated review (2006) on Helicobacter pylori as a potential target for the therapy of ischemic heart disease. Panminerva Med 2006;48(4):241–6.9. Braunwald E., Jones R.H., Mark D.B., et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994;90:613–22.Braunwald E., Jones R.H., Mark D.B., et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994;90:613–22.10. Игнатьева Т.П., Тувалева Л.С., Курамшина О.А. Заболевания желудочно-кишечного тракта как фактор риска развития ишемической болезни сердца (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):122.Игнатьева Т.П., Тувалева Л.С., Курамшина О.А. Заболевания желудочно-кишечного тракта как фактор риска развития ишемической болезни сердца (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):122.11. Куимов А.Д., Кривошеев А.Б., Хван Л.А. Клинические особенности язвенной болезни, ассоциированной с ИБС (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):124.Куимов А.Д., Кривошеев А.Б., Хван Л.А. Клинические особенности язвенной болезни, ассоциированной с ИБС (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):124.12. Медведев В.Н., Ивкова И.А., Медведева В.Н. и др. Диагностика и лечение больных язвенной болезнью желудка в сочетании с ИБС и артериальной гипертонией (тезисы). Российский гастроэнтерологический журнал 2001;(2):136.Медведев В.Н., Ивкова И.А., Медведева В.Н. и др. Диагностика и лечение больных язвенной болезнью желудка в сочетании с ИБС и артериальной гипертонией (тезисы). Российский гастроэнтерологический журнал 2001;(2):136.13. Лазебник Л.Б., Звенигородская Л.А., Горуновская И.Г. и др. Язвенная болезнь у пожилых (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):125.Лазебник Л.Б., Звенигородская Л.А., Горуновская И.Г. и др. Язвенная болезнь у пожилых (тезисы). Экспериментальная и клиническая гастроэнтерология 2004;(1):125.14.Rader D.I. Inflommatory markers of coronary risk. N Engl J Med 2000;343(16):1179–82.Rader D.I. Inflommatory markers of coronary risk. N Engl J Med 2000;343(16):1179–82.15. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836–43.Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836–43.16. Кремнева Л.В. Лейкоцитоз как показатель риска ИБС и ее обострений (обзор). Терапевтический архив 2004;76(11):30–5.Кремнева Л.В. Лейкоцитоз как показатель риска ИБС и ее обострений (обзор). Терапевтический архив 2004;76(11):30–5.17. Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология 1999;39(2):81–5. 18. Mash F., Lovis C., Gaspoz J.M., et al. C-reactive protein as a marker for acute coronary syndrome. Eur Heart J 1997;18(9):1897–902.Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология 1999;39(2):81–5. 18. Mash F., Lovis C., Gaspoz J.M., et al. C-reactive protein as a marker for acute coronary syndrome. Eur Heart J 1997;18(9):1897–902.19. Карпов Ю.А., Сорокин Е.В., Фомичева О.А. Воспаление и атеросклероз: состояние проблемы и нерешенные вопросы. Сердце 2003;2(4):190–2.Карпов Ю.А., Сорокин Е.В., Фомичева О.А. Воспаление и атеросклероз: состояние проблемы и нерешенные вопросы. Сердце 2003;2(4):190–2.20. Кульберг А.Я. Молекулярная иммунология. М.: Высшая школа, 1985.Кульберг А.Я. Молекулярная иммунология. М.: Высшая школа, 1985.21. Арутюнов Г.П., Кафарская Л.И., Власенко В.К. Микрофлора кишечника у больных хронической сердечной недостаточностью как возможный фактор возникновения и генерализации системного воспаления. Журнал Сердечная Недостаточность 2003;4(5):256–60.Арутюнов Г.П., Кафарская Л.И., Власенко В.К. Микрофлора кишечника у больных хронической сердечной недостаточностью как возможный фактор возникновения и генерализации системного воспаления. Журнал Сердечная Недостаточность 2003;4(5):256–60.22. Franceshi F., Roccarina D., Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Minerva Med 2006;97(1):39–45.Franceshi F., Roccarina D., Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Minerva Med 2006;97(1):39–45.23. Franceshi F., Gasbarrini A. Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol 2007;21(2):325–34.Franceshi F., Gasbarrini A. Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol 2007;21(2):325–34.24. Suzuki H., Marshall B.J., Hibi T. Overview: Helicobacter pylori and extragastric disease. Int J Hematol 2006;84(4):291–300.Suzuki H., Marshall B.J., Hibi T. Overview: Helicobacter pylori and extragastric disease. Int J Hematol 2006;84(4):291–300.25. Царегородцева Т.М., Серова Т.И., Трубицына И.Е. и др. Специфические антитела к Helicobacter pylori при болезнях органов пищеварения (тезисы). Медицинская иммунология 2004;6(3–5):346.Царегородцева Т.М., Серова Т.И., Трубицына И.Е. и др. Специфические антитела к Helicobacter pylori при болезнях органов пищеварения (тезисы). Медицинская иммунология 2004;6(3–5):346.26. Лазебник Л.Б., Царегородцева Т.М., Серова Т.И. и др. Антитела к Helicobacter pylori при болезнях желудка. Терапевтический архив 2006;78(2):15–9.Лазебник Л.Б., Царегородцева Т.М., Серова Т.И. и др. Антитела к Helicobacter pylori при болезнях желудка. Терапевтический архив 2006;78(2):15–9.27. Kinjo K., Sato H., Shiotani I., et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. Circ J 2002;66(9):805–10.Kinjo K., Sato H., Shiotani I., et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. Circ J 2002;66(9):805–10.28. Martines T.A., Martines G.M. Helicobacter pylori: a new cardiovascular risk factor? Rev Esp Cardiol 2002;55(6):652–6.Martines T.A., Martines G.M. Helicobacter pylori: a new cardiovascular risk factor? Rev Esp Cardiol 2002;55(6):652–6.29. Fraser A.G., Scragg R.K., Cox B., Jackson R.T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J 2003;33(7):267–72.Fraser A.G., Scragg R.K., Cox B., Jackson R.T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J 2003;33(7):267–72.30. Hoffmeister A., Rothenbacher D., Bode G., et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Tromb Vasc Biol 2001;21(3):427–32.Hoffmeister A., Rothenbacher D., Bode G., et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Tromb Vasc Biol 2001;21(3):427–32.31. Oshima T., Ozono R., Yano Y., et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol 2005;45(8):1219–22.Oshima T., Ozono R., Yano Y., et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol 2005;45(8):1219–22.32. Cai X.J., Cai H.B., Lu D. Study on the correlation of between infection, inflammation and coronary artery disease (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi 2003;24(6):503–7.Cai X.J., Cai H.B., Lu D. Study on the correlation of between infection, inflammation and coronary artery disease (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi 2003;24(6):503–7.33. Zhu J., Quyyumi A.A., Muhlestein J.B., et al. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am J Cardiol 2002;89(2):155–8.Zhu J., Quyyumi A.A., Muhlestein J.B., et al. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am J Cardiol 2002;89(2):155–8.34. Mayr M., Kiechl S., Mendall M.A., et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003;34(3):610–5.Mayr M., Kiechl S., Mendall M.A., et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003;34(3):610–5.35. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. TheKowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. Thedetection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 2001;52(1Suppl 1):3–31.36. Yusuf S.W., Mishra R.M. Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischaemic heart disease. Acta Cardiol 2002;57(5):317–22.Yusuf S.W., Mishra R.M. Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischaemic heart disease. Acta Cardiol 2002;57(5):317–22.37. Grabczewska Z., Nartowicz E. Infections with Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus and atherosclerosis (in Polish). Przegl Lek 1999;56(9):584–7.Grabczewska Z., Nartowicz E. Infections with Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus and atherosclerosis (in Polish). Przegl Lek 1999;56(9):584–7.38. Fraser A.G., Scragg R.K., Cox B., Jackson R.T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J 2003;33(7):267–72.Fraser A.G., Scragg R.K., Cox B., Jackson R.T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J 2003;33(7):267–72.39. Pellicano R., Parravicini P.P., Bigi R., et al. Infection by Helicobacter pylori and acute myocardial infarction. Do cytotoxic strains make a difference? New Microbiol 2002;25(3):315–21.Pellicano R., Parravicini P.P., Bigi R., et al. Infection by Helicobacter pylori and acute myocardial infarction. Do cytotoxic strains make a difference? New Microbiol 2002;25(3):315–21.